A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis

• DOI: 10.1067/mpd.2002.129844
• Publication Date: 2003-02-11T16:25:29Z
• Authors: Hema Patel; Robert W. Platt; Gary S. Pekeles; Francine M. Ducharme
• Keywords: Aerosols; Time Factors; Epinephrine; Nebulizers and Vaporizers; Infant; Adrenergic beta-Agonists; Length of Stay; Sodium Chloride; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Double-Blind Method; Acute Disease; Bronchiolitis, Viral; Humans; Vasoconstrictor Agents; Albuterol

In previously well infants hospitalized with acute viral bronchiolitis, the effectiveness of repeated nebulized therapy with epinephrine (EPI) was compared with treatment with albuterol (ALB) or saline placebo (PLAC).In this randomized, double-blind, parallel-group, controlled trial, infants received study nebulizations every 1 to 6 hours and were assessed twice daily by the research team. The primary outcome was length of hospital stay (LOS). Secondary outcomes included the time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress.A total of 149 infants were randomized; 50 were allocated to receive racemic EPI, 51 were given ALB, and 48 received PLAC. Baseline characteristics and pre-enrollment symptoms, signs, and therapy were similar between groups. There were no group differences in the primary outcome measure, mean LOS (hours)(+/- SD): EPI = 59.8 (62), ALB = 61.4 (54), and PLAC = 63.3 (47); P =.95 by intent-to-treat analysis. Group differences were not statistically significant in any of the secondary outcomes.There were no group differences in the effectiveness of therapy for infants hospitalized with bronchiolitis. Based on these results, we do not recommend routine use of either nebulized EPI or ALB in this patient group.